Manon de Graaf

Statistics

Publications

Citations

H-Index

Active since

2022

Affiliations

The Netherlands Cancer Institute(Current)

OLVG

VIB-KU Leuven Center for Cancer Biology

Oncode Institute

Tergooi

Manon de Graaf is an author at The Netherlands Cancer Institute specializing in immunotherapy, triple-negative breast cancer therapy, and immune checkpoint inhibitors.

ORCID

Publications per year

2022–2024

Publications

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Iris Nederlof, Olga I. Isaeva, Manon de Graaf et al. · Nature Medicine · 2024 · 67 citations · Full text

Life Sciences, Immunology, Oncology +17

LBA13 Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial

I. Nederlof, Olga I. Isaeva, N. Bakker et al. · Annals of Oncology · 2022 · 27 citations

Medicine, Immunology, Oncology +17

1–2 of 2